The aim of our study was to address the potential for improvements in thyroid cancer detection in routine clinical settings using a clinical examination, the American College of Radiology Thyroid Imaging Reporting and Database System (ACR TI-RADS), and fine-needle aspiration cytology (FNAC) concurrently with molecular diagnostics. A prospective cohort study was performed on 178 patients. DNA from FNA samples was used for next-generation sequencing to identify mutations in the genes BRAF, HRAS, KRAS, NRAS, and TERT. RNA was used for real-time PCR to detect fusion genes. The strongest relevant positive predictors for malignancy were the presence of genetic mutations (p < 0.01), followed by FNAC (p < 0.01) and ACR TI-RADS (p < 0.01). Overall, FNAC, ACR TI-RADS, and genetic testing reached a sensitivity of up to 96.1% and a specificity of 88.3%, with a diagnostic odds ratio (DOR) of 183.6. Sensitivity, specificity, and DOR decreased to 75.0%, 88.9%, and 24.0, respectively, for indeterminate (Bethesda III, IV) FNAC results. FNA molecular testing has substantial potential for thyroid malignancy detection and could lead to improvements in our approaches to patients. However, clinical examination, ACR TI-RADS, and FNAC remained relevant factors.

Department of Pathology University Hospital Kralovske Vinohrady 3rd Faculty of Medicine Charles University Srobarova 1150 50 10034 Prague Czech Republic

Institute of Endocrinology Narodni 8 11694 Prague Czech Republic

Internal Clinic University Hospital Kralovske Vinohrady 3rd Faculty of Medicine Charles University Srobarova 1150 50 10034 Prague Czech Republic

Zobrazit více v PubMed

Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. PubMed DOI PMC

Horvath E., Silva C.F., Majlis S., Rodriguez I., Skoknic V., Castro A., Rojas H., Niedmann J.-P., Madrid A., Capdeville F., et al. Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting and Data System) classification: Results in surgically resected thyroid nodules. Eur. Radiol. 2016;27:2619–2628. doi: 10.1007/s00330-016-4605-y. PubMed DOI

Kim E.-K., Park C.S., Chung W.Y., Oh K.K., Kim D.I., Lee J.T., Yoo H.S. New Sonographic Criteria for Recommending Fine-Needle Aspiration Biopsy of Nonpalpable Solid Nodules of the Thyroid. Am. J. Roentgenol. 2002;178:687–691. doi: 10.2214/ajr.178.3.1780687. PubMed DOI

Middleton W.D., Teefey S.A., Reading C.C., Langer J.E., Beland M.D., Szabunio M.M., Desser T.S. Comparison of Performance Characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association Guidelines. Am. J. Roentgenol. 2018;210:1148–1154. doi: 10.2214/AJR.17.18822. PubMed DOI

U.S. Preventive Services Task Force Screening for Thyroid Cancer: Recommendation Statement. Am. Fam. Physician. 2018;97 PubMed

Nguyen X.V., Choudhury K.R., Tessler F.N., Hoang J.K. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines. Thyroid. 2018;28:295–300. doi: 10.1089/thy.2017.0526. PubMed DOI

Bongiovanni M., Spitale A., Faquin W.C., Mazzucchelli L., Baloch Z.W. The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis. Acta Cytol. 2012;56:333–339. doi: 10.1159/000339959. PubMed DOI

Nikiforov Y.E., Baloch Z.W. Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology. Cancer Cytopathol. 2019;127:225–230. doi: 10.1002/cncy.22112. PubMed DOI PMC

Lu Z., Zhang Y., Feng D., Sheng J., Yang W., Liu B. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 2017;8:45784–45792. doi: 10.18632/oncotarget.17412. PubMed DOI PMC

Valderrabano P., Leon M.E., Centeno B.A., Otto K.J., Khazai L., McCaffrey J.C., Russell J.S., McIver B. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur. J. Endocrinol. 2016;174:621–629. doi: 10.1530/EJE-15-1163. PubMed DOI

Steward D.L., Carty S.E., Sippel R.S., Yang S.P., Sosa J.A., Sipos J.A., Figge J.J., Mandel S., Haugen B.R., Burman K.D., et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Indeterminate Cytology. JAMA Oncol. 2019;5:204–212. doi: 10.1001/jamaoncol.2018.4616. PubMed DOI PMC

Guth S., Theune U., Aberle J., Galach A., Bamberger C.M. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur. J. Clin. Investig. 2009;39:699–706. doi: 10.1111/j.1365-2362.2009.02162.x. PubMed DOI

Zamrazil V., Bilek R., Cerovska J., Delange F. The Elimination of Iodine Deficiency in the Czech Republic: The Steps Toward Success. Thyroid. 2004;14:49–56. doi: 10.1089/105072504322783849. PubMed DOI

Bai Y., Kakudo K., Jung C.K. Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. Endocrinol. Metab. 2020;35:696–715. doi: 10.3803/EnM.2020.807. PubMed DOI PMC

Grant E.G., Tessler F.N., Hoang J.K., Langer J.E., Beland M.D., Berland L.L., Cronan J.J., Desser T.S., Frates M.C., Hamper U.M., et al. Thyroid Ultrasound Reporting Lexicon: White Paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. J. Am. Coll. Radiol. 2015;12:1272–1279. doi: 10.1016/j.jacr.2015.07.011. PubMed DOI

Tessler F.N., Middleton W.D., Grant E.G., Hoang J.K., Berland L.L., Teefey S.A., Cronan J.J., Beland M.D., Desser T.S., Frates M.C., et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J. Am. Coll. Radiol. 2017;14:587–595. doi: 10.1016/j.jacr.2017.01.046. PubMed DOI

Cibas E.S., Ali S.Z. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27:1341–1346. doi: 10.1089/thy.2017.0500. PubMed DOI

Pekova B., Sykorova V., Dvorakova S., Vaclavikova E., Moravcova J., Katra R., Astl J., Vlcek P., Kodetova D., Vcelak J., et al. RET, NTRK, ALK, BRAF, and MET Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas. Thyroid. 2020;30:1771–1780. doi: 10.1089/thy.2019.0802. PubMed DOI

Meloun M., Hill M., Militky J., Kupka K. Transformation in the PC-Aided Biochemical Data Analysis. Clin. Chem. Lab. Med. (CCLM) 2000;38:553–559. doi: 10.1515/CCLM.2000.081. PubMed DOI

Trygg J., Wold S. Orthogonal projections to latent structures (O-PLS) J. Chemom. 2002;16:119–128. doi: 10.1002/cem.695. DOI

Grimmichová T., Pačesová P., Srbová L., Vrbíková J., Havrdová T., Hill M. The Gold Standard of Thyroid Nodule Examination? Prospective Validation of the ACR TI-RADS in a Secondary Referral Center. Physiol. Res. 2020;69:S329–S337. doi: 10.33549/physiolres.934515. PubMed DOI PMC

Takano T. Natural history of thyroid cancer. Endocr. J. 2017;64:237–244. doi: 10.1507/endocrj.EJ17-0026. PubMed DOI

Williams D. Thyroid Growth and Cancer. Eur. Thyroid J. 2015;4:164–173. doi: 10.1159/000437263. PubMed DOI PMC

Coca-Pelaz A., Shah J.P., Hernandez-Prera J.C., Ghossein R.A., Rodrigo J.P., Hartl D.M., Olsen K.D., Shaha A.R., Zafereo M., Suarez C., et al. Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review. Adv. Ther. 2020;37:3112–3128. doi: 10.1007/s12325-020-01391-1. PubMed DOI PMC

Lin J.S., Bowles E.J.A., Williams S.B., Morrison C.C. Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017;317:1888–1903. doi: 10.1001/jama.2017.0562. PubMed DOI

Nam I.-C., Choi H., Kim E.-S., Mo E.-Y., Park Y.-H., Sun D.-I. Characteristics of thyroid nodules causing globus symptoms. Eur. Arch. Otorhinolaryngol. 2015;272:1181–1188. doi: 10.1007/s00405-015-3525-9. PubMed DOI

Malone M.K., Zagzag J., Ogilvie J., Patel K., Heller K.S. Thyroid Cancers Detected by Imaging Are Not Necessarily Small or Early Stage. Thyroid. 2014;24:314–318. doi: 10.1089/thy.2012.0651. PubMed DOI

Grimmichova T., Haluzik M., Vondra K., Matucha P., Hill M. Relation of prediabetes and type 2 diabetes mellitus to thyroid cancer. Endocr. Connect. 2020;9:607–616. doi: 10.1530/EC-20-0180. PubMed DOI PMC

Anil C., Goksel S., Gursoy A. Hashimoto’s Thyroiditis Is Not Associated with Increased Risk of Thyroid Cancer in Patients with Thyroid Nodules: A Single-Center Prospective Study. Thyroid. 2010;20:601–606. doi: 10.1089/thy.2009.0450. PubMed DOI

Lopes N.M.D., Lens H.H.M., Armani A., Marinello P.C., Cecchini A.L. Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes. Pathol. Res. Pract. 2020;216:153098. doi: 10.1016/j.prp.2020.153098. PubMed DOI

Pantano A.L., Maddaloni E., Briganti S.I., Anguissola G.B., Perrella E., Taffon C., Palermo A., Pozzilli P., Manfrini S., Crescenzi A. Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound classifications performance in identifying cytological high-risk thyroid nodules. Eur. J. Endocrinol. 2018;178:595–603. doi: 10.1530/EJE-18-0083. PubMed DOI

Koc A.M., Adıbelli Z.H., Erkul Z., Sahin Y., Dilek I. Comparison of diagnostic accuracy of ACR-TIRADS, American Thyroid Association (ATA), and EU-TIRADS guidelines in detecting thyroid malignancy. Eur. J. Radiol. 2020;133:109390. doi: 10.1016/j.ejrad.2020.109390. PubMed DOI

Ng D.L., van Zante A., Griffin A., Hills N.K., Ljung B.-M.E. A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up. Thyroid. 2021;31:1086–1095. doi: 10.1089/thy.2020.0689. PubMed DOI PMC

Paschke R., Cantara S., Crescenzi A., Jarzab B., Musholt T.J., Simoes M.S. European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics. Eur. Thyroid J. 2017;6:115–129. doi: 10.1159/000468519. PubMed DOI PMC

Haddad R.I., Nasr C., Bischoff L., Busaidy N.L., Byrd D., Callender G., Dickson P., Duh Q.-Y., Ehya H., Goldner W., et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J. Natl. Compr. Cancer Netw. 2018;16:1429–1440. doi: 10.6004/jnccn.2018.0089. PubMed DOI

Gharib H., Papini E., Garber J.R., Duick D.S., Harrell R.M., Hegedüs L., Paschke R., Valcavi R., Vitti P. AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical endocrinologists, american college of endocrinology, and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules 2016 UPDATE. Endocr. Pract. 2016;22:622–639. doi: 10.4158/EP161208.GL. PubMed DOI

Niemeier L.A., Akatsu H.K., Song C., Carty S.E., Hodak S.P., Yip L., Ferris R.L., Tseng G.C., Seethala R.R., Lebeau S.O., et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2011;118:2069–2077. doi: 10.1002/cncr.26425. PubMed DOI PMC

Zheng X., Wei S., Han Y., Li Y., Yu Y., Yun X., Ren X., Gao M. Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases. Ann. Surg. Oncol. 2013;20:2266–2273. doi: 10.1245/s10434-012-2851-z. PubMed DOI

Melo M., da Rocha A.G., Vinagre J., Batista R., Peixoto J., Tavares C., Celestino R., Almeida A., Salgado C., Eloy C., et al. TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. J. Clin. Endocrinol. Metab. 2014;99:E754–E765. doi: 10.1210/jc.2013-3734. PubMed DOI PMC

Lee S.E., Hwang T.S., Choi Y.-L., Han H.S., Kim W.S., Jang M.H., Kim S.K., Yang J.H. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAFV600E Mutation–Prevalent Population. Thyroid. 2016;26:901–910. doi: 10.1089/thy.2015.0488. PubMed DOI

Pekova B., Sykorova V., Mastnikova K., Vaclavikova E., Moravcova J., Vlcek P., Lastuvka P., Taudy M., Katra R., Bavor P., et al. NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis. Cancers. 2021;13:1932. doi: 10.3390/cancers13081932. PubMed DOI PMC

Ito Y., Miyauchi A., Kihara M., Higashiyama T., Kobayashi K., Miya A. Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation. Thyroid. 2014;24:27–34. doi: 10.1089/thy.2013.0367. PubMed DOI PMC

Marina M., Zatelli M.C., Goldoni M., Del Rio P., Corcione L., Martorana D., Percesepe A., Bonatti F., Mozzoni P., Crociara A., et al. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: Results from a single-institution prospective study. J. Endocrinol. Investig. 2021;44:2635–2643. doi: 10.1007/s40618-021-01571-y. PubMed DOI PMC

Figge J.J., Gooding W.E., Steward D.L., Yip L., Sippel R.S., Yang S.P., Scheri R.P., Sipos J.A., Mandel S.J., Mayson S.E., et al. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid. 2021;31:1673–1682. doi: 10.1089/thy.2021.0119. PubMed DOI PMC

Zhu Y., Wu H., Huang B., Shen X., Cai G., Gu X. BRAFV600E mutation combined with American College of Radiology thyroid imaging report and data system significantly changes surgical resection rate and risk of malignancy in thyroid cytopathology practice. Gland Surg. 2020;9:1674–1684. doi: 10.21037/gs-20-535. PubMed DOI PMC

Type 2 Diabetes, Obesity and Their Relation to the Risks of Thyroid Cancer

Genetic Changes in Thyroid Cancers and the Importance of Their Preoperative Detection in Relation to the General Treatment and Determination of the Extent of Surgical Intervention-A Review